பிரியாங்க புல்லா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Healthcare workers transfer the body of a person who died from COVID-19, at a hospital in Kolkata, May 12, 2021. Photo: Reuters/Rupak De Chowdhuri Mumbai: On May 1, the Drug Controller General of India (DCGI) approved a drug called 2-deoxy-d-glucose (2-DG) for emergency use among people with moderate and severe COVID-19, to help manage the disease. This drug was jointly developed by researchers at the Institute of Nuclear Medicine and Allied Sciences, which falls under the Defence Research & Development Organisation (DRDO), and the pharmaceutical giant Dr Reddy’s Laboratories. In line with the DCGI’s approval for favipiravir, itolizumab and Verafin, the approval for 2-DG is based on poor evidence.

West bengalAndhra pradeshDrug administrationIndian council of medical researchMinistry of defenceCentre for cellularMinistry of defence press information bureauMahatma gandhi institute of medical sciencesInstitute of nuclear medicinePatanjali research instituteDefence research development organisationDrug controller generalNuclear medicineAllied sciencesDefence researchDevelopment organisation